CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
The efficacy of MMX™ mesalazine as the sole medication for the induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis treated over 14–16 months
DOI 10.1055/s-0028-1089402
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Schreiber
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: MMX Multi Matrix System™ (MMX) mesalazine (MEZAVANT™; MEZAVANT™ XL [UK and Ireland]; LIALDA™ [USA]) has demonstrated efficacy for the induction of remission of mild-to-moderate ulcerative colitis (UC) in two phase III, placebo-controlled trials (SPD476–301 and -302) and for the maintenance of remission in a phase III, open-label extension study (SPD476–303). In this analysis, we have calculated the pro…
Zitieren
Zitierempfehlung
S Schreiber (2008) The efficacy of MMX™ mesalazine as the sole medication for the induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis treated over 14–16 months. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0028-1089402
Mit CareLit weiterarbeiten